Summary: A single dose of psilocybin, the active compound found in psychedelic magic mushrooms, can significantly reduce chronic nerve pain and dramatically boost the performance of conventional painkillers.
The research demonstrates that psilocybin physically restructures the brain’s pain-processing networks rather than merely blocking pain signals. This structural reset provides sustained relief for up to a month and causes gabapentin, a widely prescribed but frequently ineffective nerve medication, to work with vastly superior efficacy long after the psilocybin has cleared from the body.
Key Facts
- The Persistent Reset: A single injection of psilocybin delivered long-lasting pain relief to mice with nerve damage, with effects appearing roughly two hours post-dose and persisting for several weeks. Because the relief outlasts the physical presence of the compound, researchers conclude that psilocybin fundamentally restructures how the brain processes pain networks.
- The Gabapentin Catalyst: The study’s most remarkable milestone centered on a powerful drug synergy. When gabapentin was administered weeks later—after the psilocybin’s standalone pain relief had completely worn off—it produced an extended wave of relief lasting up to four days. In control models with no prior psilocybin exposure, gabapentin’s effects were drastically weaker.
- The Clinical Care Gap: Chronic nerve pain is notoriously difficult to manage, leaving between 30% and 50% of human patients completely unable to find adequate relief using gabapentin alone.
- Bypassing Addiction Risks: Senior author Dr. Maria Maiarú noted that current high-tier pain medications frequently carry severe side effects or high risks of addiction. By resetting the brain’s internal network to make existing non-addictive treatments work better, this therapy offers a transformative alternative for patients who have run out of clinical options.
- Cross-Sex Validation: Unlike early historical pain research that suffered from a heavy male bias, this study explicitly confirmed equal pain-relieving efficacy across both male and female animal models.
- Ethical Execution: In strict alignment with UK Home Office regulations and the 3Rs principles (Replacement, Reduction, and Refinement), the study design minimized distress and captured multiple data outcomes from a small, optimized cohort of animals.
Source: University of Reading
A single dose of psilocybin — the active compound in magic mushrooms — reduces nerve pain for up to a month and makes a widely used painkiller work more effectively, University of Reading research has found.
The study, published in Communications Biology, tested psilocybin in mice with nerve damage that causes long-lasting pain.
Researchers found that psilocybin’s pain-relieving effect appeared around two hours after injection, with relief lasting several weeks. Rather than simply blocking pain signals, psilocybin appears to restructure the way the brain’s pain-processing networks operate, which may explain why its effects persist long after the drug itself has left the body.
The most significant finding was how psilocybin interacted with gabapentin, a drug widely prescribed for nerve pain. When gabapentin was given to mice weeks after a single psilocybin dose, after psilocybin’s own pain-relieving effect had worn off, it produced pain relief lasting up to four days. In mice that had not received psilocybin, gabapentin’s effect was much weaker.
Between 30 and 50 percent of people with nerve pain do not get adequate relief from gabapentin alone.
Dr Maria Maiarú, senior author from the University of Reading, said: “Millions of people live with nerve pain that their medication simply does not control well enough, and the medicines we do have can cause serious side effects or lead to addiction.
“What is exciting here is that psilocybin does not just reduce pain on its own. It appears to reset the brain’s pain networks in a way that makes existing treatments significantly more effective. For patients who have run out of options, that could be genuinely transformative.”
The pain-relieving effect was confirmed in both male and female mice, which is significant given that much early pain research was conducted in male animals only.
The study used a small number of mice in line with UK Home Office regulations and the 3Rs principles of Replacement, Reduction and Refinement. Procedures were designed to minimise distress, and where possible multiple outcomes were measured from the same animals to keep numbers down.
Key Questions Answered:
A: Psilocybin doesn’t just act like a chemical band-aid that temporarily blocks a pain signal from traveling up your spine. Instead, the University of Reading discovered that it actually steps into the brain and physically rewires and restructures the entire pain-processing network. Because it alters the baseline architecture of how the brain interprets these signals, the pain-relieving effects lock in and persist long after the drug has left your system.
A: It essentially primes the canvas. When researchers gave gabapentin to subjects weeks after their psilocybin dose, at a point where the psilocybin’s own pain relief had completely faded, the gabapentin suddenly worked like a miracle drug, knocking out pain for up to four days straight. By resetting the brain’s internal network, the psychedelic makes the brain hyper-receptive to existing medications, unlocking a near-doubling of therapeutic power.
A: No, and that is what makes this synergy so clinically beautiful. Because the psilocybin functions as a long-term network reset, a patient would theoretically only need a single, isolated dose to restructure their pathways. From that point forward, their standard, non-psychedelic daily medications could do the heavy lifting with flawless efficiency, eliminating the need for chronic psychedelic use or heavy, addictive painkillers.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this pain and psychedelics research news
Author: Ollie Sirrell
Source: University of Reading
Contact: Ollie Sirrell – University of Reading
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia” by Tatum Askey, Daniel Allen-Ross, Daniil Luzyanin, Reena Lasrado, Gary Gilmour, Stephen P. Hunt, Francesco Tamagnini, Maqsood Ahmed, Gary J. Stephens & Maria Maiarú. Communications Biology
DOI:10.1038/s42003-026-10065-7
Abstract
Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
Chronic pain states remain challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin produces a sustained anti-nociceptive effect in chronic neuropathic pain models in male and female mice, mediated primarily by 5-HT2A receptors.
Critically, psilocybin significantly potentiates the analgesic efficacy of gabapentin, a standard-of-care treatment, representing the first preclinical evidence that a psychedelic can serve as a pain-network primer for existing analgesics.
This finding represents a novel therapeutic strategy with potential clinical application, particularly for the 30-50% of neuropathic pain patients who fail gabapentin monotherapy. Our data demonstrate that a single psilocybin injection produces sustained month-long changes that enhance gabapentin efficacy in a preclinical model of human pain.
Together, these findings indicate that psilocybin both acutely enhances analgesia and induces lasting changes that amplify gabapentin efficacy weeks later. Such a translation is notable in chronic pain management, where most analgesics require chronic dosing and lose efficacy through tolerance.
These findings establish psilocybin as a potential therapeutic addition for pain management by enabling longer-lasting changes in pain-processing networks and enhancing the utility of established treatments.
